Central Nervous System Oncology
Genenta Science S.p.A. focuses on glioblastoma multiforme and other malignant neoplasms of the central nervous system, with clinical research centered on advanced neuro-oncology and the management of aggressive brain tumors.
- Glioblastoma multiforme
- Malignant neoplasms of the central nervous system
- Hematopoietic stem cell-based treatment
The sponsor’s trial portfolio in this area reflects interest in gene therapy approaches for hard-to-treat central nervous system cancers.
Renal Cell Carcinoma
Clinical research also extends to metastatic renal cell carcinoma, including patients with locally advanced or metastatic disease and progression after standard treatment, highlighting interest in advanced genitourinary oncology.
- Metastatic renal cell carcinoma
- Locally advanced disease
- Post-standard-of-care progression
This area links oncology and cell-based gene therapy in a setting of limited treatment options.
Gene Therapy and Cell-Based Medicine
Genenta Science’s studies are built around Temferon and hematopoietic stem cells, placing genetic medicine and cell therapy at the center of its research activity.
- Temferon
- Hematopoietic stem cells
- Gene-modified cellular therapy
The sponsor’s clinical work emphasizes therapeutic applications of engineered cells in solid tumors.
Long-Term Safety and Biological Activity
Research interests include long-term mutagenic safety, treatment tolerability, and the biological effects of therapy following administration, with attention to both patient safety and therapeutic activity.
- Mutagenic safety
- Tolerability
- Biological activity
These areas are relevant to the clinical development of advanced oncology treatments.
